Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02200614
Title Efficacy and Safety Study of ODM-201 in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
Recruitment Completed
Gender male
Phase Phase III
Variant Requirements No
Sponsors Orion Corporation, Orion Pharma
Indications

prostate adenocarcinoma

Therapies

Darolutamide

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.